De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature

Table 3 De novo malignancy features in orthotopic liver transplant recipients: The Tor Vergata experience between April 1998 and December 2014

	Patients under standard IS,n = 234Median age: 53.6 ± 7.1 yr	Tolerant patients,n = 22Median age: 52.3 ± 6.0 yr	Non-tolerant patients, n = 43Median age: 51.5 ± 9.6 yr
Number of patients	234	22	43
Median follow-up time from OLT to IS weaning, mo	-	112.9	59.8
Median follow-up time from weaning start to IS withdrawal, mo	-	6.0	4.9
Median follow-up time with no IS, mo	-	92.3	2.3
Median follow-up time after IS resumption, mo	-	-	149.1
Patients who developed DNMs, %	13.7	0	6.4
Median time from OLT to DNM development, mo	44.5	-	113.0
Incidence and type of DNMs	(n = 32) Lung (7) Head and neck (5) Colon (4) Oral cavity (4) PTLD (4) Genito-urinary (3) Esophagus (2) Liver (1) Mesothelioma (1) KS (1)	None	Bladder (1) Larynx (1) Lung (1)

DNM: De novo malignancy; OLT: Orthotopic liver transplant; IS: Immunosuppression; PTLD: Post-transplant lymphoproliferative diseases; KS: Kaposi’s sarcoma.